Retia Medical Receives FDA 510(k) Clearance for Argos Infinity™, Expanding Cardiovascular Intelligence Across High-Risk Surgical and Critical Care Environments
WHITE PLAINS, NEW YORK, UNITED STATES — February 16, 2026 — Retia Medical today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for Argos Infinity™, the company’s cardiovascular intelligence software platform designed for high-risk surgical and critical care environments across health systems.
Argos Infinity builds on Retia’s clinically validated Multi Beat Analysis® (MBA®) algorithm and analyzes real-time physiologic data streams from existing monitoring and tele-ICU systems. By transforming routine signals into actionable cardiovascular insight, Argos Infinity supports earlier recognition of hemodynamic instability in operating rooms and intensive care units.
